Primary biliary cirrhosis: paradigm or paradox for autoimmunity.
Primary biliary cirrhosis: paradigm or paradox for autoimmunity.
复制标题
原发性胆汁性肝硬化:自身免疫的范例或悖论。
DOI:
10.1016/0016-5085(91)80033-6
复制
发表时间:
1991
期刊:
影响因子:
29.4
通讯作者:
Mackay,IR
中科院分区:
文献类型:
--
作者:
Gershwin,ME;Mackay,IR
Primary biliary cirrhosis has been classified as a model autoimmune disease based on striking defects in immune regulation and the presence of autoantibodies to mitochondria. Until recently the significance and definition of mitochondrial autoreactivity was unknown. Since 1987, there has been a vast improvement in the understanding and definition of the biochemical and molecular target autoantigens. The cloning of complementary DNAs for mitochondrial antigens has led to the identification of three enzymes of the 2-oxo-acid dehydrogenase family as the targets of the autoantibodies to mitochondria in patients with primary biliary cirrhosis. The major reactive autoantigen is the E2 subunit of pyruvate dehydrogenase. Immunodominant sites on pyruvate dehydrogenase E2 (autoepitopes) have been mapped and have been shown to be the site of attachment of the functionally important lipoic acid prosthetic group. The autoepitope for the other enzymes probably occupies an equivalent site on the enzyme. The availability and definition of these mitochondrial autoepitopes have allowed specific questions to be addressed relating to the processing and targeting of these autoantigens as well as further studies on mechanisms of immunopathology. Similarly, the availability of well-defined autoantigens could contribute to the development of valid animal models in addition to the already described reproduction of the biliary ductular lesions by transfer of peripheral blood lymphocytes from patients with primary biliary cirrhosis into severe combined immunodeficient mice. Such models will facilitate specific study of the role of major histocompatibility complex expression and the characterization of T-cell reactivity. Thus, primary biliary cirrhosis is a key example of significant progress in autoimmunity being made by use of recombinant DNA technology.
登录
查看更多内容
DOI:
10.1056/nejm195801232580407
发表时间:
1958-01
期刊:
The New England journal of medicine
影响因子:
--
作者:
I. Mackay
通讯作者:
I. Mackay
DOI:
10.1002/j.1460-2075.1986.tb04631.x
发表时间:
1986
期刊:
The EMBO Journal
影响因子:
--
作者:
H. Theissen;M. Etzerodt;R. Reuter;C. Schneider;F. Lottspeich;P. Argos;R. Lührmann;L. Philipson
通讯作者:
L. Philipson
DOI:
--
发表时间:
1989
期刊:
Seminars in liver disease (Print)
影响因子:
--
作者:
I. Mackay;Gershwin Me
通讯作者:
Gershwin Me
DOI:
--
发表时间:
1974
期刊:
影响因子:
--
作者:
I. B. Elfenbein;R. Mcalack;D. Mills;E. Munoz;J. Milder;M. Côté
通讯作者:
M. Côté
DOI:
10.4049/jimmunol.142.11.3815
发表时间:
1988
期刊:
The FASEB Journal
影响因子:
--
作者:
M. Gershwin;Aftab J. Ahmed;D. Danner;D. Fregeau;P. Leung;R. Coppel
通讯作者:
R. Coppel